Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PPM1B | O75688 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.40 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3081295 | 1.00 | POLB (0.47) | POLBKMT2AMEN1USP2ALDH1A1 | |
| SCHEMBL3238065 | 1.00 | POLB (0.47) | POLBKMT2AMEN1USP2ALDH1A1 | |
| SCHEMBL18681189 | 1.00 | POLB (0.47) | POLBKMT2AMEN1USP2ALDH1A1 | |
| SCHEMBL16258710 | 1.00 | POLB (0.47) | POLBKMT2AMEN1USP2ALDH1A1 | |
| SCHEMBL14853797 | 1.00 | POLB (0.47) | POLBKMT2AMEN1USP2ALDH1A1 | |
| SCHEMBL24522365 | 1.00 | POLB (0.47) | POLBKMT2AMEN1USP2ALDH1A1 | |
| SCHEMBL14586081 | 1.00 | POLB (0.47) | POLBKMT2AMEN1USP2ALDH1A1 | |
| SCHEMBL12556245 | 1.00 | POLB (0.47) | POLBKMT2AMEN1USP2ALDH1A1 | |
| SCHEMBL21007945 | 1.00 | POLB (0.47) | POLBKMT2AMEN1USP2ALDH1A1 | |
| SCHEMBL16918612 | 1.00 | POLB (0.47) | POLBKMT2AMEN1USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014033617-A1 | 2'-ETHYNYL NUCLEOSIDE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS AG (CH) | 2014-03-06 | — | — | WO | disclosed |
| US-8299038-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| WO-2012125900-A1 | 2'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20090280086-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX PHARMACEUTICALS LLC | 2009-11-12 | — | — | US | disclosed |
| US-7192936-B2 | Use treating hepatitis C infection optionally with other viricides such as interferons or ribavirin; low toxicity to the host; use of cytosine-based nucleotides or nucleosides having a 2'-trifluoromethyl-ribose moiety which forms a 5'-phosphate or hydroxy moiety in vivo | IDENIX PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070060503-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-03-15 | — | — | US | disclosed |
| US-20070027065-A1 | Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-7163929-B2 | Methods and compositions for treating flaviviruses and pestiviruses | IDENIX PHARMACEUTICALS, INC. (US) | 2007-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280086-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | HAVCR2, HCCS, PYGL | POLB 842/4885KMT2A 3715/4885MEN1 4420/4885 |
| US-20070060503-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | PNP, NSUN2, HAVCR2 | POLB 271/4885KMT2A 2920/4885MEN1 4834/4885 |
| US-20070027065-A1 | Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | PNP, UGT1A3, SLC29A2 | POLB 1586/4885KMT2A 3223/4885MEN1 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.